Tìm theo
Ibritumomab
Các tên gọi khác (2) :
  • Ig gamma-2A chain C region, membrane-bound form
  • radiolabeled murine anti-CD20
Thuốc Gốc
Biotech
CAS: 174722-31-7
ATC: V10XX02
ĐG : Spectrum Pharmaceuticals , http://www.spectrumpharm.com
CTHH: C6382H9830N1672O1979S54
PTK: 143375.5000
Indium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and two kappa light chains of 213 amino acids each.
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
C6382H9830N1672O1979S54
Phân tử khối
143375.5000
Độ tan chảy
61 °C (FAB fragment), 71 °C (whole mAb)
Độ kỵ nước
-0.359
Điểm đẳng điện tích
7.91
Dược Lực Học : Ibritumomab is a murine monoclonal antibody against CD20 that has been radiolabeled with yttrium-90.
Cơ Chế Tác Dụng : Indium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and two kappa light chains of 213 amino acids each. The Fab segment of the antibody targets the CD20 epitope on B-cells, allowing the radioactive yttrium to destroy the cell via production of beta particles.
Dược Động Học :

▧ Volume of Distribution :
Binding observed on lymphoid cells of the bone marrow, lymph node, thymus, red and white pulp of the spleen, lymphoid follicles of the tonsil, and lymphoid nodules of other organs (e.g., large and small intestines)
▧ Metabolism :
Most likely removed by opsonization via the reticuloendothelial system when bound to B cells, or by human antimurine antibody production
▧ Half Life :
0.8 hours (mammalian reticulocytes, in vitro)
▧ Clearance :
Approximately 7.2% of injected dose of yttrium Y 90 ibritumomab tiuxetan is excreted in urine within 7 days.
Chỉ Định : For treatment of non-Hodgkin's lymphoma
Tương Tác Thuốc :
  • Belimumab Avoid combination due to enhanced adverse effects of belimumab.
  • Clozapine Avoid combination due to enhanced adverse effects of clozapine, including agranulocytosis.
  • Denosumab Monitor therapy for enhanced immunosuppressive effects and increased risk of infections.
  • Eptifibatide Monitor therapy due to enhanced adverse effects, ie bleeding of ibritumomab.
  • Leflunomide May need to modify therapy to avoid adverse effects of leflunomide such as hematologic toxicity.
  • Natalizumab Avoid combination due to increased adverse effects of natalizumab and increased risk of infections.
  • Pimecrolimus Avoid combination due to increased immunosuppressive effects.
  • Roflumilast Consider modifying therapy due to enhanced immunosuppressive effect.
  • Sipuleucel-T Monitor therapy due to diminished therapeutic effect of sipuleucel-t.
  • Tacrolimus Avoid combination due to enhanced adverse effects of immunosuppressants.
  • Tofacitinib Avoid combination due to enhanced immunosuppressive effect of tofacitinib.
  • Trastuzumab Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
  • Trastuzumab Monitor therapy due to enhanced neutropenic effect of immunosuppressants.
Dữ Kiện Thương Mại
Giá thị trường
  • Biệt dược thương mại : Zevalin in-111 kit
    Giá bán buôn : USD >4200.0
    Đơn vị tính : kit
  • Biệt dược thương mại : Zevalin y-90 kit
    Giá bán buôn : USD >37800.0
    Đơn vị tính : kit
Nhà Sản Xuất
Đóng gói
... loading
... loading